


# PRODUCT INFORMATION



## Isoursodeoxycholic Acid

Item No. 34620

**CAS Registry No.:** 78919-26-3  
**Formal Name:** (3 $\beta$ ,5 $\beta$ ,7 $\beta$ )-3,7-dihydroxy-cholan-24-oic acid  
**Synonyms:** isoUDCA, IUDCA, 3 $\beta$ -Ursodeoxycholic Acid  
**MF:** C<sub>24</sub>H<sub>40</sub>O<sub>4</sub>  
**FW:** 392.6  
**Purity:**  $\geq$ 98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:**  $\geq$ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Isoursodeoxycholic acid is supplied as a solid. A stock solution may be made by dissolving the isoursodeoxycholic acid in the solvent of choice, which should be purged with an inert gas. Isoursodeoxycholic acid is soluble in the organic solvent methanol.

### Description

Isoursodeoxycholic acid is a 3 $\beta$ -epimer of the secondary bile acid ursodeoxycholic acid (UDCA; Item No. 15121).<sup>1</sup> It is formed from UDCA via epimerization *in vivo* and can be isomerized back into UDCA.<sup>1,2</sup> Isoursodeoxycholic acid (2,500 mg/kg in the diet) decreases serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine transaminase (ALT) levels in bile duct-ligated rats but does not affect liver histology.<sup>3</sup>

### References

1. Marschall, H.-U., Broomé, U., Einarsson, C., *et al.* Isoursodeoxycholic acid: Metabolism and therapeutic effects in primary biliary cirrhosis. *J. Lipid Res.* **42**(5), 735-742 (2001).
2. Beuers, U., Fischer, S., Spengler, U., *et al.* Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. *J. Hepatol.* **13**(1), 97-103 (1991).
3. Purucker, E., Marschall, H.-U., Winograd, R., *et al.* Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. *Biochim. Biophys. Acta* **1526**(1), 44-52 (2001).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)